FutureTox V: New Technologies to Evaluate Organ-Specific Effects of Drugs and Chemicals will focus on issues of interest to regulatory and investigative toxicologists and discuss new technologies and strategies that are being used to improve, reduce, and/or replace animal testing (3Rs). The conference also will have presentations on computational analysis and artificial intelligence (AI). For example, new technologies will need to be developed to meet the computational challenges that genomics poses for the near future—given highly distributed data acquisition that involves heterogeneous formats—as well as emerging opportunities for data reduction and real-time analysis.
The FutureTox series focuses on building the road for 21st-century toxicology and risk assessment practices, utilizing in vitro data and in silico models for predictive toxicology, and taking the high-throughput risk assessment paradigm forward to address challenges in implementing the emerging big-data toolbox for risk assessment and regulatory decision-making.
Microphysiological Systems (MPS) and Engineered Microtissues:
These represent 3D tissue function in a way that more realistically represents human organ function and can be used in efficacy and safety testing for pharma, disease models and therapies, and hazard identification for environmental chemical management programs. Important issues are in the capacity to recapitulate or invoke human disease processes utilizing integrated and translational multi-omics approaches, bioinformatics, AI-based computational models, and multi-chip circuits.
Novel Cross-Cutting Technologies:
These involve single cell transcriptomics, novel imaging tools, and other emerging cutting-edge methods for breaking down cellular functions into subtype-specific effects that are topographically linked to tissue physiology and organ function. Elucidating “subtype cellular functions” promises to revolutionize the way to assess local changes in a tissue that cascade from toxicant-induced changes at single cell resolution to altered organ function.
Computational Integration and Synthesis:
Mechanistic understanding of biological and toxicological processes is becoming increasingly dependent on big data. AI (e.g., machine and deep learning) and virtual-reality technologies are examples of data-related innovations that herald a new era for biomedical research, requiring quantitative systems for extracting knowledge and concepts.
Managing Expectations:
Short-term and long-term activities for pragmatic use of technologies to answer questions on organ-specific toxicity (e.g., 2D versus 3D, screening versus targeted testing, in vitro to in vivo extrapolation, kinetics and dynamics, etc.) will be addressed in the discussion and breakout group sessions.
By presenting these cross-cutting topics (e.g., technology used in a tissue type and big data), it is expected that individuals working on the technology side will learn about potential new applications, scientists working on a type of toxicity will become educated about new approaches they might use in their field, and all will become acquainted with ways to store and utilize the resulting data.
When using the mail-in registration form, payment must be submitted in one of the following ways:
Submit your completed registration via:
Registration Cancellation Refund Policy: All requests for cancellations and/or refunds must be received in writing to SOT Headquarters. These refunds will be processed, less a $30 fee, following the CCT meeting by April 18, 2022.
SOT reserves the right to review all registrations and to determine that individuals or organizations meet the Society’s criteria for participation.
SOT looks forward to seeing you in Chapel Hill, North Carolina for FutureTox V: New Technologies to Evaluate Organ-Specific Effects of Drugs and Chemicals and is prioritizing the safety of all meeting participants in planning for and conducting the event.
The Society is monitoring safety, health, and travel guidance from the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO), and state and local health authorities. SOT will continually adjust its processes for the event in accordance with these directives.
Reviewed May 2022
There are no restrictions or measures imposed by executive order for the public. There are no travel restrictions in place for North Carolina, and visitors do not have to quarantine upon arrival. All guests attending a meeting on the UNC Chapel Hill campus must abide by UNC’s Community Standards, including, if applicable at the time of the meeting, complying with any mask requirements.
Ivan Rusyn, Texas A&M University, College Station, TX
Lorna Ewart, Emulate, Boston, MA
– Perfused Microphysiological Systems
Lawrence Vernetti, University of Pittsburgh, Pittsburgh, PA
– Liver Spheroids and Micropatterned Cultures
Salman Khetani, University of Illinois at Chicago, Chicago, IL
– Discussion of the Advantages/Disadvantages and Barriers to the Application of These Models or Data from These Models in Decision-Making
Discussants: Lawrence Vernetti; Salman Khetani; and Donna L. Mendrick, US FDA, Silver Spring, MD
– Perfused Microphysiological Systems
Michael Workman, Cedars-Sinai Medical Center, Los Angeles, CA
– Neurospheroid Models
Lena Smirnova, Johns Hopkins University, Baltimore, MD
– Discussion of the Advantages/Disadvantages and Barriers to the Application of These Models or Data from These Models in Decision-Making
Discussants: Michael Workman; Lena Smirnova
– Intestinal Enteroids
Mark Donowitz, Johns Hopkins University, Baltimore, MD
– Modeling the Gut Microbiome
Hyun Jung Kim, University of Texas at Austin, Austin, TX
– Discussion of the Advantages/Disadvantages and Barriers to the Application of These Models or Data from These Models in Decision-Making
Discussants: Mark Donowitz; Hyun Jung Kim
– Perfused Microphysiological Systems
Kevin Healy, University of California Berkeley, Berkeley, CA
– High-Throughput In Vitro Models for Precision Medicine and Population-Based Testing
Alison Motsinger-Reif, NIEHS, Research Triangle Park, NC
– Discussion of the Advantages/Disadvantages and Barriers to the Application of These Models or Data from These Models in Decision-Making
Discussants: Kevin Healy; Alison Motsinger-Reif; Weihsueh Chiu, Texas A&M University, College Station, TX
– Perfused Microphysiological Systems
Dan Huh, University of Pennsylvania, Philadelphia, PA
– Air-Liquid Interface Models for Airway Safety Assessment
Alex Charlton , Syngenta, Research Triangle Park, NC
– Discussion of the Advantages/Disadvantages and Barriers to the Application of These Models or Data from These Models in Decision-Making
Discussants: Dan Huh; Alex Charlton
– Opportunities to Advance IVIVE with Physiological Organ-Specific Models
Weihsueh Chiu, Texas A&M University, College Station, TX
– Discussion of IVIVE Science Needs of the New Toxicology Models
Discussants: Weihsueh Chiu; John F. Wambaugh, US EPA, Research Triangle Park, NC; and Barbara A. Wetmore, US EPA, Research Triangle Park, NC
Thomas B. Knudsen, US EPA, Research Triangle Park, NC
James A. Glazier, Indiana University Bloomington, Bloomington, IN
– Novel Single Cell Sequencing-Based Technologies
James Cai, Texas A&M University, College Station, TX
– Novel Imaging-Based Technologies (e.g., Bioimaging)
Serguei Liachenko, US FDA/NCTR, Jefferson, AR
– In Silico Models of Organ-Specific Effects
Thomas B. Knudsen, US EPA
Discussion of the Advantages/Disadvantages and Barriers to the Application of These Technologies or Data from These Models in Decision-Making
Discussants: James Cai; Thomas B. Knudsen; Serguei Liachenko; Donna L. Mendrick, US FDA
BREAKOUT 1:
Chairs: Donna L. Mendrick, US FDA, Silver Spring, MD; and Katie Paul Friedman, US EPA, Research Triangle Park, NC
What are future research needs in the areas of new technologies to evaluate organ-specific effects of drugs and chemicals?
BREAKOUT 2:
Chairs: Suzanne C. Fitzpatrick, US FDA, College Park, MD; and Sid Hunter, US EPA, Research Triangle Park, NC
What are the opportunities for the regulators to use new models and technologies in evaluating organ-specific effects of drugs and chemicals?
BREAKOUT 3:
Chairs: Michele Taylor, US EPA, Research Triangle Park, NC; and Nicole C. Kleinstreuer, NIEHS/NICEATM, Research Triangle Park, NC
What “Big Data” streams are being used in toxicology and risk assessment, especially in the realm of organ-specific toxicity? What tools are generalizable to more traditional, yet complex data streams
Abstracts should relate to the topics and themes for this CCT meeting and submission is open to all FutureTox V attendees. Registration status will be confirmed before publication, and only conference attendees' work will appear at the meeting and in program materials. There is no fee associated with submission. For additional details on topics and themes, please visit the “Background” section of this website. Further instructions for poster preparation will be shared upon acceptance. Accepted abstracts will be displayed during the poster session on Tuesday, May 10, 2022.
Graduate students and postdoctoral scholars are encouraged to submit abstracts. Based on availability of funding, travel support will be provided to graduate students and postdoctoral scholars based on the merit of their submitted abstract and confirmation of their presenting a poster at the FutureTox V conference. Awards will be presented only to those individuals who attend the conference and present a poster.
Users will be directed to Oxford Abstracts, where you must create an account to submit your abstract.
All submissions must be received by 11:00 PM ET on Friday, April 8, 2022.
There is a wide variety of hotel accommodations in the area. The listing below includes recommendations from the Chapel Hill Convention and Visitor Bureau, sorted by distance from the Friday Center.
Become a Sponsor
Interested in becoming a sponsor? Learn about the opportunities and benefits of sponsorship.
Request Info 11190 Sunrise Valley Drive, Suite 300, Reston, VA 20191-4375
703.438.3115
sothq@toxicology.org